Literature DB >> 10711449

Health profile preferences of hepatitis C patients.

J R Treadwell1, D Kearney, M Davila.   

Abstract

The side effects of interferon-alpha for chronic hepatitis C are well-known. Patients may differ with respect to their tolerance of these side effects and also with respect to their individual preferences. We administered a brief questionnaire to 67 outpatients with hepatitis C virus infection. Patients were asked to make hypothetical choices between six-month profiles of health. The results were as follows: (1) patients preferred to expedite rather than postpone intervals of poor health; (2) preferences of patients with low quality-of-life were quite similar to preferences of healthier patients; (3) patients' choices satisfied transitivity; (4) patients' choices satisfied preferential independence; and (5) patients gave a variety of reasons for their choices. These results corroborate other investigations of health preferences, and serve to introduce the field of preference elicitation to gastroenterologists.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10711449     DOI: 10.1023/a:1005420828332

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  13 in total

1.  Tests of preferential independence in the QALY model.

Authors:  J R Treadwell
Journal:  Med Decis Making       Date:  1998 Oct-Dec       Impact factor: 2.583

Review 2.  A criticism of healthy-years equivalents.

Authors:  P Wakker
Journal:  Med Decis Making       Date:  1996 Jul-Sep       Impact factor: 2.583

3.  In the eye of the beholder: assessment of health-related quality of life.

Authors:  D K Owens
Journal:  Hepatology       Date:  1998-01       Impact factor: 17.425

4.  A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity.

Authors:  J Ware; M Kosinski; S D Keller
Journal:  Med Care       Date:  1996-03       Impact factor: 2.983

Review 5.  Side effects of alpha interferon in chronic hepatitis C.

Authors:  G Dusheiko
Journal:  Hepatology       Date:  1997-09       Impact factor: 17.425

6.  Modeling therapeutic benefit in the midst of uncertainty: therapy for hepatitis C.

Authors:  W G Bennett; S G Pauker; G L Davis; J B Wong
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

7.  Quality-adjusted life years, utility theory, and healthy-years equivalents.

Authors:  A Mehrez; A Gafni
Journal:  Med Decis Making       Date:  1989 Apr-Jun       Impact factor: 2.583

8.  Healthy-years equivalents versus quality-adjusted life years: in pursuit of progress.

Authors:  A Mehrez; A Gafni
Journal:  Med Decis Making       Date:  1993 Oct-Dec       Impact factor: 2.583

9.  [Evaluation of side effects of interferon-alpha in 72 patients treated for chronic active hepatitis C].

Authors:  A Duché; G Decocq; D Capron-Chivrac; M Andréjak
Journal:  Therapie       Date:  1995 Sep-Oct       Impact factor: 2.070

10.  Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis.

Authors:  G R Foster; R D Goldin; H C Thomas
Journal:  Hepatology       Date:  1998-01       Impact factor: 17.425

View more
  4 in total

1.  Testing transitivity of preferences on two-alternative forced choice data.

Authors:  Michel Regenwetter; Jason Dana; Clintin P Davis-Stober
Journal:  Front Psychol       Date:  2010-12-13

2.  Patients' preferences for treatment of hepatitis C.

Authors:  Liana Fraenkel; Diane Chodkowski; Joseph Lim; Guadalupe Garcia-Tsao
Journal:  Med Decis Making       Date:  2009-07-27       Impact factor: 2.583

3.  Preferences for antiviral therapy of chronic hepatitis C: a discrete choice experiment.

Authors:  Axel C Mühlbacher; John F P Bridges; Susanne Bethge; Ch-Markos Dintsios; Anja Schwalm; Andreas Gerber-Grote; Matthias Nübling
Journal:  Eur J Health Econ       Date:  2016-02-04

4.  Physicians' preference values for hepatitis C health states and antiviral therapy: a survey.

Authors:  R Patil; S J Cotler; G Banaad-Omiotek; R A McNutt; M D Brown; S Cotler; D M Jensen
Journal:  BMC Gastroenterol       Date:  2001-08-01       Impact factor: 3.067

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.